The present invention relates to amphiphilic aminoglycoside (AG) derivatives especially derivatives of tobramycin kanamycin A and paromomycin comprising hydrophobic side chains linked to the AG moiety by various linkers. These novel derivatives are useful as broad spectrum antibacterial agents targeting bacterial cell membranes while having minimal toxicity due to non-selective targeting of eukaryotic cell membranes. The present invention further relates to methods for preparing the novel deriva...

This invention discloses a method of inducing expression of full-length collagen 7 in cells that contain nonsense mutations in the COL7A1 gene by treating the cell with an aminoglycoside such as G418 gentamicin and paromomycin. Also provided is a method of treating DEB due to nonsense mutation in the COL7A1 gene by administering a composition containing an effective amount of an aminoglycoside. Also provided is a novel composition useful to treating conditions due to nonsense mutation in the COL...

PURPOSE: A composition containing a Piper longum L. extract for preventing and treating inner ear damage is provided to suppress the reduction of sensory hair cells. CONSTITUTION: A pharmaceutical composition for preventing and treating inner ear damage contains a Piper longum L. extract as an active ingredient. The inner ear damage is caused by apoptosis of sensory hair cells and is due to aminoglycoside antibiotics. The aminoglycoside antibiotics include amikacin arbekacin gentamycin kanamycin...

This invention discloses a method of inducing expression of full-length collagen 7 in cells that contain nonsense mutations in the gene by treating the cell with an aminoglycoside such as G418 gentamicin and paromomycin. Also provided is a method of treating DEB due to nonsense mutation in the gene by administering a composition containing an effective amount of an aminoglycoside. Also provided is a novel composition useful to treating conditions due to nonsense mutation in the gene containing a...

A new class of paromomycin-derived aminoglycosides (Formula I), which exhibit efficient stop-codon mutation suppression activity, low cytotoxicity and selectivity towards eukaryotic cells are provided. Also provided are processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

This invention discloses a method of inducing expression of full-length collagen 7 in cells that contain nonsense mutations in the COL7A1 gene by treating the cell with an aminoglycoside such as G418 gentamicin and paromomycin. Also provided is a method of treating DEB due to nonsense mutation in the COL7A1 gene by administering a composition containing an effective amount of an aminoglycoside. Also provided is a novel composition useful to treating conditions due to nonsense mutation in the COL...

This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.DNA topoisomerase I (Top1) is the target of camptothecin and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors d...